tesamorelin for injection — United Healthcare

Initial criteria

• Diagnosis of HIV-associated lipodystrophy

Reauthorization criteria

• Documentation of positive clinical response (e.g., improvement in visceral adipose tissue, decrease in waist circumference, belly appearance) while on Egrifta therapy

Approval duration

12 months